(April 28, 2016, 1:41 PM EDT) -- WASHINGTON, D.C. — Two chemical companies argue to the U.S. Supreme Court in an April 15 brief that an appellate court properly considered Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. (135 S.Ct. 831 [2105]) and, thus, should deny a petition for review of district courts’ factual findings on whether patent claims are vague only for clear errors or if they should conduct their own analyses instead (Dow Chemical Co. v. NOVA Chemicals Corp. [Canada] and NOVA Chemicals, Inc. [Delaware], Nos. 15-1160, U.S. Sup.)....